Last reviewed · How we verify

Placebo of HS-25

Zhejiang Hisun Pharmaceutical Co. Ltd. · Phase 3 active Small molecule

Placebo of HS-25 is a Small molecule drug developed by Zhejiang Hisun Pharmaceutical Co. Ltd.. It is currently in Phase 3 development.

This is a placebo control arm and contains no active pharmaceutical ingredient.

At a glance

Generic namePlacebo of HS-25
SponsorZhejiang Hisun Pharmaceutical Co. Ltd.
ModalitySmall molecule
PhasePhase 3

Mechanism of action

As a placebo, HS-25 placebo is an inert formulation used as a control comparator in clinical trials. It is designed to match the appearance and administration route of the active HS-25 drug to maintain blinding in phase 3 studies, but contains no active drug substance and produces no pharmacological effect.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo of HS-25

What is Placebo of HS-25?

Placebo of HS-25 is a Small molecule drug developed by Zhejiang Hisun Pharmaceutical Co. Ltd..

How does Placebo of HS-25 work?

This is a placebo control arm and contains no active pharmaceutical ingredient.

Who makes Placebo of HS-25?

Placebo of HS-25 is developed by Zhejiang Hisun Pharmaceutical Co. Ltd. (see full Zhejiang Hisun Pharmaceutical Co. Ltd. pipeline at /company/zhejiang-hisun-pharmaceutical-co-ltd).

What development phase is Placebo of HS-25 in?

Placebo of HS-25 is in Phase 3.

Related